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Abstract
Objective—To characterize subsequent pregnancy outcomes among women with a history of 
previable, preterm prelabor rupture of membranes (PROM) and assess factors associated with 
recurrent preterm birth.
Methods—This was a retrospective cohort study of women cared with a history of ≥1 singleton 
pregnancy complicated by preterm PROM <24.0 weeks of gestation between 2002–2013 who 
cared for in 2 tertiary care health systems by a single group of maternal-fetal medicine specialists. 
Women were identified using ICD-9 codes and obstetric databases. Those with iatrogenic preterm 
PROM and those whose index preterm PROM <24.0 weeks was preceded by advanced cervical 
dilation were excluded. All women with ≥1 pregnancy reaching the second trimester after an index 
previable, preterm PROM pregnancy were included. The primary outcome was recurrent preterm 
birth <37 weeks. Data were analyzed by chi-square, Fisher’s exact, t-test, Wilcoxon rank-sum, and 
logistic regression.
Results—Two hundred ninety four women had ≥1 pregnancy complicated by previable, preterm 
PROM. One hundred eight out of 294 (37%) had ≥1 subsequent pregnancy in our healthcare 
systems and50/108 (46%) had ≥2. In the pregnancy immediately after the index delivery, the risk 
of prematurity was high: 50 (46%) delivered at <37 weeks, 31 (30%) at <34 weeks, 25 (23%) <28 
weeks, and 18 (17%) before 24 weeks of gestation. Fewer than half (N=49, 45%) of women 
received preterm birth prophylaxis (progesterone or cerclage) in a subsequent pregnancy; rates of 
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recurrent preterm birth were similar among women who received preterm birth prophylaxis 
compared to those who did not. In regression models, the only factor significantly associated with 
recurrent preterm birth <37 weeks was a history of preterm birth preceding previable, preterm 
PROM delivery (aOR 3.23, 95% CI 1.32–7.93).
Conclusion—Patients with history of previable, preterm PROM are at high risk of recurrent 
preterm birth.
Introduction
Preterm prelabor rupture of membranes (PROM) complicates 3–4.5% of all pregnancies and 
is responsible for approximately 1/3 of all premature births.(1, 2) Previable, preterm PROM 
(< 24.0 weeks) is associated with high rates of neonatal morbidity and mortality and occurs 
in <1% of all pregnancies.(3–6)
Traditionally, women delivering <20.0 weeks of gestation have not been regarded to have a 
preterm birth history, but rather, a miscarriage; such women have been excluded from 
intervention trials [including the Meis, et al. RCT of 17 alpha hydroxyprogesterone caproate 
vs. placebo].(7) Recently, experts have challenged this arbitrary 20.0 week cutoff to 
distinguish between “preterm birth” and “miscarriage.” Studies suggest that women with a 
history of a prior preterm birth between 16 and 20 weeks of gestation have an increased risk 
of recurrent second trimester loss and recurrent early preterm birth.(8) Thus, many experts 
recommend treating women with pregnancy loss due to spontaneous preterm labor, 
asymptomatic cervical dilation, or preterm PROM at 16–20 weeks similarly to those with 
this history >20.0 weeks. Management options include prematurity prevention clinic 
enrollment, prophylactic 17-alpha hydroxyprogesterone caproate, prophylactic cerclage, or 
increased cervical length surveillance.(9–13) In this investigation, we sought to characterize 
subsequent pregnancy outcomes among women with a history of preterm PROM <24.0 
weeks and assess utilization of preterm birth prophylaxis modalities.
Materials and Methods
This was a retrospective cohort study that included all women with one or more documented 
singleton pregnancies complicated by preterm PROM between 14.0 and 24.0 weeks of 
gestation between 2002–2013 (index pregnancy) who then had at least one subsequent 
pregnancy reaching at least the 2nd trimester (≥14.0 weeks of gestation) between 2003 and 
2015. Those with recognized cervical insufficiency (advanced cervical dilation in the 
absence of uterine contractions) preceding the occurrence of the index previable, preterm 
PROM were excluded. Women were also excluded if their fetus had major structural 
congenital malformations or aneuploidy, or if preterm PROM occurred within 1 week of 
amniocentesis or cervical cerclage placement. Women with a history of previable, preterm 
PROM who received care at one of 2 tertiary healthcare systems (The University of Utah 
and Intermountain Healthcare Hospitals) from a single group of maternal-fetal medicine 
specialists were identified using International Classification of Diseases (ninth revision) 
using established obstetric databases, and all cases were verified by manual chart review. 
Women referred for preconception counseling or prenatal care in a subsequent pregnancy 
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following previable, preterm PROM were also included. All subsequent pregnancies 
reaching at least 14 weeks of gestation in the same 2 healthcare systems were studied..
Data abstracted from the medical records were collected and managed using REDCap 
(Research Electronic Data Capture) electronic data collection tool hosted at the University of 
Utah Center for Clinical and Translational Science.(16) Data were de-identified and 
therefore informed consent was waived. The University of Utah and Intermountain 
Healthcare Institutional Review Boards approved this study.
The primary outcome was recurrent preterm birth <37.0 weeks of gestation due to any 
indication in the first pregnancy following the index previable, preterm PROM. Secondary 
outcomes included recurrent preterm birth <34.0 weeks, <28.0 weeks, and prior to fetal 
viability (<24.0 weeks), as well as recurrent previable, preterm PROM <24.0 weeks, 
subsequent pregnancy surveillance with transvaginal cervical length ultrasound, or use of 
prophylactic progesterone or cerclage. We also sought to examine pregnancy outcomes for 
the second and third subsequent pregnancies following index previable, preterm PROM, as 
applicable.
Univariable analyses were by Chi-square analysis, Fisher exact test, Student t-test, Wilcoxon 
rank-sum as appropriate. Multivariable logistic regression was performed including variables 
selected using stepwise backward elimination; factors with p<0.20 remained in final models. 
All data were analyzed using STATA software version 13.1 (STATA Corp, College Station, 
TX).
Results
We identified 294 women with at least 1 pregnancy complicated by previable, preterm 
PROM <24.0 weeks of gestation during the study period (2002–2013). Of these, 108/294 
(37%) had at least one subsequent pregnancy in our healthcare system and met inclusion 
criteria (Figure 1).
Four women were found to have had their first previable, preterm PROM deliveries prior to 
the previable, preterm PROM delivery that occurred during 2002–2013. For the purposes of 
data analysis, the earliest pregnancy where previable, preterm PROM could be documented 
was considered the index previable, preterm PROM case, and the next documented 
subsequent pregnancy to reach the second trimester was studied, even if these pregnancies 
were earlier than the initial time window specified by the inclusion criteria, provided the 
woman was confirmed to have a delivery complicated by previable, preterm PROM during 
the 2002–2013 search window.
Women with a history of previable, preterm PROM were at high risk for preterm birth <37.0 
weeks of gestation in subsequent pregnancies (Figure 2). Overall, 50% had at least one 
subsequent preterm birth (Figure 1). When only the first subsequent pregnancy reaching the 
second trimester was considered, 50 women (46%, 95% CI 37–56%) delivered preterm 
<37.0 weeks of gestation, 31 (30%, 95% CI 23–41%) delivered <34.0 weeks, 25 (23%, 95% 
CI 16–32%) <28.0 weeks, and 18 (17%, 95% CI 11–25%) delivered <24.0 weeks of 
gestation. There were no indicated preterm deliveries (e.g., for maternal or fetal indications) 
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in this cohort; all preterm birth were attributed to spontaneous preterm labor, preterm 
PROM, or cervical insufficiency. Women whose first pregnancy after previable, preterm 
PROM delivered preterm <37.0 weeks were more likely to have a history of a prior preterm 
birth and less likely to have had a prior term delivery, but were otherwise similar to those 
who delivered at term in the subsequent pregnancy. Specifically, the median gestational ages 
at previable, preterm PROM and at delivery of the index previable, preterm PROM 
pregnancy were similar between groups (Table 1). Recurrent previable, preterm PROM was 
also common; 20 women (19%, 95% CI 12–27%) had one or more subsequent pregnancies 
complicated by recurrent preterm PROM <24.0 weeks of gestation.
Fifty of the 108 women (46%, 95%CI 37–56%) had two or more subsequent pregnancies 
reaching the second trimester. For those with multiple subsequent pregnancies, if the first 
subsequent pregnancy delivered at term, there was an increased rate of term delivery in the 
second subsequent pregnancy (90%, 95% CI 71–97%), Figure 2. Six women of 46 (13%, 
95% CI 6–27%) with uterine cavity evaluations were found to have uterine cavity 
abnormalities, including 2 with a uterine septum and 4 with a bicornuate uterus.
Use of prematurity prevention interventions (including 17-alpha hydroxyprogesterone 
caproate administration and cervical cerclage placement) occurred in 49/108 (45%, 95% CI 
36–54%) of women in their first pregnancy after previable, preterm PROM (Table 2). There 
were no changes over the study period in use of cervical cerclage or vaginal progesterone. 
However, there was increased use of 17-alpha hydroxyprogesterone caproate among those 
who had their first subsequent pregnancy later in the study period (Pearson’s correlation 
coefficient r=0.433, p<0.001). Eight women delivered their next pregnancy before 2004. 
Although use of 17-alpha hydroxyprogesterone caproate increased later in the study period, 
of the 100 women who delivered in an era of 17-alpha hydroxyprogesterone caproate use 
(2004 or later), 17-alpha hydroxyprogesterone caproate use was low, and our ability to make 
conclusions regarding efficacy in this population are limited by small numbers (Table 2). 
Specifically, overall 13% (n=7, 95% CI 7–29%) women used 17-alpha hydroxyprogesterone 
caproate from 2004–2009, vs. 50% (n=23, 95% CI 35–65%) from 2010–2014. In the time of 
increased use from 2010–2014, 34% (95% CI 17–57%) of those receiving 17-alpha 
hydroxyprogesterone caproate delivered preterm; although this rate was lower than the 48% 
(95% CI 27–69%) preterm birth rate among the 23 women who did not receive 17-alpha 
hydroxyprogesterone caproate, it was not statistically significant (p=0.369).
There was also a lower rate of pre-viable delivery (<24.0 weeks of gestation) with 17-alpha 
hydroxyprogesterone caproate use across the entire study period, but this analysis was also 
limited by small numbers (2/28, 6.7% delivered <24.0 weeks with 17-alpha 
hydroxyprogesterone caproate compared with 16/62, 21% delivered <24.0 weeks without 
17-alpha hydroxyprogesterone caproate, p=0.147). We also examined the proportion of 
women who were “eligible” to receive 17-alpha hydroxyprogesterone caproate using strict 
inclusion criteria by limiting “eligibility” to delivery at or beyond 20.0 weeks of gestation as 
per the original study by Meis et al. We found that 42/66 (63%, 95% CI 53–72%) women 
who delivered their previable, preterm PROM pregnancy ≥20.0 weeks (who had a 
subsequent pregnancy delivering in or beyond 2004) were not given 17-alpha 
hydroxyprogesterone caproate in any subsequent pregnancy.
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In regression models, a history of preterm birth prior to the previable, preterm PROM 
delivery was associated with recurrent preterm birth <37.0 weeks (Table 3).
Discussion
In our cohort, nearly half of subsequent pregnancies after previable, preterm PROM resulted 
in preterm birth, and women with this history were at risk for recurrent preterm birth at 
<34.0, <28.0, and <24.0 weeks of gestation, as well as recurrent previable, preterm PROM. 
More alarmingly, 17% of women in this cohort delivered their immediately-ensuing 
pregnancy <24.0 weeks of gestation.
Recent studies have emphasized the importance of precisely determining the preterm birth 
phenotype in order to predict clinical outcomes. (17–19) This cohort exemplifies these 
concepts, as women with a prior preterm birth who then have previable, preterm PROM 
carry an extremely high risk for subsequent recurrent preterm birth and recurrent previable 
delivery. In all, 6/46 (13%, 95% CI 6–27%) women had an abnormal uterine cavity. For 
comparison, the expected rate of Mullerian anomalies in an unselected population is 3–6%; 
our study design prevents direct comparison of these rates.(20, 21) Previous studies have 
also found an association between uterine anomalies and preterm birth, second trimester 
pregnancy loss, miscarriage and infertility.(21–23) If some preterm birth may be attributed 
to mechanical causes, this may aid counseling and management; surgical repair of uterine 
anomalies may prolong gestation for some women.(24–26)
Various approaches to preterm birth prophylaxis are recommended for pregnant women with 
a history of spontaneous preterm birth. All women with ≥1 prior spontaneous preterm birth 
should receive prophylaxis with weekly intramuscular 17-alpha hydroxyprogesterone 
caproate injections between 16–36 weeks of gestation.(11, 27) In this cohort, only 30% of 
those with a history of previable, preterm PROM reaching the 2nd trimester received 17-
alpha hydroxyprogesterone caproate. Though 17-alpha hydroxyprogesterone caproate use 
was higher from 2010 to 2014, it was still only 50%. This low rate of 17-alpha 
hydroxyprogesterone caproate utilization does not appear unique to our study population. 
Several recent reports have demonstrated 17-alpha hydroxyprogesterone caproate utilization 
among eligible women ranges from 39% to 47%.(28, 29). The reasons for our observed low 
utilization rate of 17-alpha hydroxyprogesterone caproate are unclear.
Our study has limitations. Due to the sample size, our ability to make conclusions regarding 
the efficacy of certain preterm birth prevention strategies (including vaginal and 
intramuscular progesterone) was limited. Interpretation of results should take into account 
the study population. For example, rates of recurrence in other populations, in the setting of 
increased cervical length screening and more widespread 17-OHPC use may be lower. In 
contrast, cohorts with more African-American women may have higher rates due to known 
increased risk of recurrent preterm birth. We were also limited by data available in the 
electronic medical record; some factors (e.g., maternal smoking) were inconsistently 
collected and therefore could not be included. We considered previable, preterm PROM to 
be <24 weeks of gestation in accordance with local practice patterns and ACOG 
recommendations regarding resuscitation. (30)
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This study has several strengths. This is a relatively large cohort of women with a strictly 
defined history of previable, preterm PROM, all with at least one subsequent pregnancy 
reaching the second trimester. It adds to the limited data describing subsequent pregnancy 
outcomes in this specific high risk population. Due to the structure of healthcare delivery 
system in Utah, two-thirds of women delivering in the State of Utah are captured by our 
database, reducing the possibility that our data are biased towards worse outcomes and that 
individuals with subsequent healthy pregnancies would have received care and delivered 
elsewhere.29
Because previable, preterm PROM is relatively uncommon, adequately powered RCTs of 
management strategies for future pregnancies are unlikely. Thus, consideration should be 
given to uterine cavity evaluation (with consideration of repair if an abnormality is found) 
and using evidence-based treatments extrapolated from more heterogeneous preterm birth 
intervention studies. In all cases, care should be individualized but should include 
counseling regarding the likelihood of recurrence of this severe preterm birth phenotype.
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Figure 1. 
Study enrollment
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Figure 2. 
Subsequent pregnancy outcomes following pre-viable preterm premature rupture of 
membranes, by pregnancy sequence.
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Table 1
Demographic, baseline, and prior pregnancy characteristics dichotomized by the delivery gestational age of the 
next pregnancy reaching the second trimester.
Characteristic Next Pregnancy after 
previable, Preterm 
PROM Delivered 
Preterm <37 weeks of 
gestation
N=50
Next Pregnancy after 
previable, Preterm 
PROM delivered at Term 
≥37 weeks of gestation
N=58
p-value
Maternal age at due date of next pregnancy after previable, 
preterm PROM, (mean ± SD)
31.3 ± 5.6 31.0 ± 5.3 0.758
White race, n(%) 43 (86) 51 (88) 0.766
Married, n(%) 36 (72) 50 (86) 0.068
Pregestational diabetes mellitus, n(%) 3 (6) 1 (2) 0.241
Chronic hypertension, n(%) 4 (8) 3 (5) 0.552
Maternal psychiatric disorder (anxiety, depression, and/or 
bipolar), n(%)
13 (26) 10 (17) 0.268
Median rupture GA of index previable, preterm PROM 
pregnancy, weeks (IQR)
20.1 (18.6 – 22.0) 20.9 (18.7 – 22.1) 0.720
Median delivery GA of index previable, preterm PROM 
pregnancy, weeks (IQR)
22.0 (20.0–24.0) 23.3 (20.7–25.4) 0.105
Index previable, preterm PROM occurred in first pregnancy (G1), 
n(%)
12 (24) 16 (28) 0.672
History of one or more preterm birth prior to previable, preterm 
PROM (among multiparous patients), n(%)
19 (38) 7 (12) 0.002
History of one or more term births prior to previable, preterm 
PROM (among multiparous patients), n(%)
17/38 (45) 28/42 (67) 0.048
Known Müllerian anomaly, n(%), among those with uterine cavity 
evaluation or delivering by cesarean
5/24 (21) 1/21 (5) 0.193
Index previable, preterm PROM complicated by chorioamnionitis, 
n(%)
14 (28) 8 (14) 0.068
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Table 2
Management or characteristics of next pregnancy after previable, preterm PROM dichotamized by delivery 
gestational age.
Characteristic Next Pregnancy After 
Previable Preterm 
PROM Delivered 
Preterm
N=50
Next Pregnancy After 
Previable Preterm PROM 
Delivered at Term
N=58
p-value
Median interpregnancy interval, years (IQR) 2 (1–3) 2 (1–3) 0.565
At least one cervical length assessment by transvaginal 
ultrasound, n(%)
22 (44) 14 (24) 0.029
Cervical cerclage placement, n(%) 18 (36) 12 (21) 0.077
Received vaginal progesterone, n(%) 2 (4) 2 (3) >0.99
Intramuscular progesterone supplementation, n(%)* 13/46 (28) 17/54 (31) 0.726
Any preterm birth prophylaxis (vaginal progesterone, 
intramuscular progesterone, or cerclage), n(%)
26 (52) 23 (40) 0.199
Clinical and/or pathologic evidence of chorioamnionitis noted at 
delivery, n(%)
13 (26) 3 (5) 0.003
*Only the 100 pregnancies delivering in 2004 or later considered
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Table 3
Multivariable regression of factors associated with delivery <37 weeks of gestation of the next pregnancy after 
previable, preterm PROM.
Characteristic Crude OR p-value aOR p-value
History of a preterm delivery prior to previable, preterm PROM 3.39 (1.46–7.86) 0.004 3.23 (1.32–7.93) 0.010
Index previable, preterm PROM complicated by chorioamnionitis 2.43 (0.92–6.40) 0.072 2.26 (0.80–6.43) 0.125
Müllerian anomaly 6.33 (0.71–56.2) 0.097 8.56 (0.90–81.4) 0.062
Married 0.41 (0.16–1.08) 0.072 0.45 (0.16–1.30) 0.142
*Other factors considered for inclusion in model but removed (p>0.20) included treatment with any preterm birth preventative intervention 
(cerclage, vaginal progesterone, and/or intramuscular progesterone – considered as a single variable)
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